SMYD3 and breast carcinoma: More importantly, the expression of SMYD3 is undetectable or very weak in most types of normal human tissue and significantly elevated in tumor tissue (e.g., colorectal cancer, hepatocellular carcinoma, prostate cancer, breast cancer, and ccRCC),[14, 41] which makes SMYD3 an ideal target with relatively few off‐target effects.